The complementary roles of dynamic contrast-enhanced MRI and $[\text{superscript 18}]$F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis


http://dx.doi.org/10.1007/s00259-013-2518-4

Publisher
Springer Berlin Heidelberg

Accessed
Sat Dec 22 15:48:47 EST 2018

Citable Link
http://hdl.handle.net/1721.1/109447

Terms of Use
Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use.

Detailed Terms

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.
The complementary roles of dynamic contrast-enhanced MRI and ¹⁸F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis

Claudia Calcagno · Sarayu Ramachandran · David Izquierdo-Garcia · Venkatesh Mani · Antoine Millon · David Rosenbaum · Ahmed Tawakol · Mark Woodward · Jan Bucerius · Erin Mosher · James Godbold · David Kallend · Michael E. Farkouh · Valentin Fuster · James H. F. Rudd · Zahi A. Fayad

Received: 11 April 2013 / Accepted: 11 July 2013 / Published online: 14 August 2013
© Springer-Verlag Berlin Heidelberg 2013

Abstract

Purpose Inflammation and neovascularization in vulnerable atherosclerotic plaques are key features for severe clinical events. Dynamic contrast-enhanced (DCE) MRI and FDG PET are two noninvasive imaging techniques capable of quantifying plaque neovascularization and inflammatory infiltrate, respectively. However, their mutual role in defining plaque vulnerability and their possible overlap has not been thoroughly investigated. We studied the relationship between DCE-MRI and ¹⁸F-FDG PET data from the carotid arteries of 40 subjects.

Electronic supplementary material The online version of this article (doi:10.1007/s00259-013-2518-4) contains supplementary material, which is available to authorized users.
with coronary heart disease (CHD) or CHD risk equivalent, as a substudy of the dal-PLAQUE trial (NCT00655473).

Methods The dal-PLAQUE trial was a multicenter study that evaluated dalcetrapib, a cholesteryl ester transfer protein modulator. Subjects underwent anatomical MRI, DCE-MRI and 18F-FDG PET. Only baseline imaging and biomarker data (before randomization) from dal-PLAQUE were used as part of this substudy. Our primary goal was to evaluate the relationship between DCE-MRI and 18F-FDG PET data. As secondary endpoints, we evaluated the relationship between (a) PET data and whole-vessel anatomical MRI data, and (b) DCE-MRI and matching anatomical MRI data. All correlations were estimated using a mixed linear model.

Results We found a significant inverse relationship between several perfusion indices by DCE-MRI and 18F-FDG uptake by PET. Regarding our secondary endpoints, there was a significant relationship between plaque burden measured by anatomical MRI with several perfusion indices by DCE-MRI and 18F-FDG uptake by PET. No relationship was found between plaque composition by anatomical MRI and DCE-MRI or 18F-FDG PET metrics.

Conclusion In this study we observed a significant, weak inverse relationship between inflammation measured as 18F-FDG uptake by PET and plaque perfusion by DCE-MRI. Our findings suggest that there may be a complex relationship between plaque inflammation and microvascularization during the different stages of plaque development. 18F-FDG PET and DCE-MRI may have complementary roles in future clinical practice in identifying subjects at high risk of cardiovascular events.

Keywords DCE-MRI · PET/CT · Atherosclerosis · Inflammation · Neovascularization

Introduction

In recent years, significant progress has been made in defining the hallmarks of high-risk, vulnerable atherosclerotic plaques. Vulnerable atheromas are characterized by a large lipid-rich necrotic core (LRNC), thin fibrous cap and prominent inflammatory infiltrate accompanied by abundant and fragile neovessels [1]. This knowledge has stimulated the development of novel, noninvasive imaging techniques to identify vulnerable plaques, with the aim of improving risk stratification, follow-up and management of therapeutic intervention by directly preventing acute events [2]. Techniques such as non-contrast-enhanced, anatomical MRI, CT and ultrasonography can quantify anatomical characteristics and detect key components of vulnerable plaques. Other techniques can extract quantitative information about molecular mechanisms within the plaque. 18F-FDG PET with CT and dynamic contrast-enhanced (DCE) MRI allow measurement of inflammation [3–5] and neovascularization [6–9], respectively, two features of plaque vulnerability. Both techniques show reasonable reproducibility [5, 10] and have been used to track antiatherosclerotic therapies in both clinical and preclinical trials [11–16]. However, the possible degree of overlap of the information provided by each test has not been thoroughly investigated. In this study, we investigated the relationship between 18F-FDG PET/CT and DCE-MRI data from the common carotid arteries of 40 subjects with either coronary heart disease (CHD) or CHD risk factors (CHD risk equivalent) recruited as part of the dal-PLAQUE multicenter trial (NCT00655473) [14, 15].

Methods

Study design

This study was conducted as part of the dal-PLAQUE multicenter trial that evaluated dalcetrapib, a cholesteryl ester transfer protein modulator [14, 15]. The protocol was reviewed and approved by the institutional review board of each participating center. Each participating center was trained in the image acquisition protocol by the core laboratory for image analysis of the dal-PLAQUE trial (Icahn School of Medicine at Mount Sinai, New York, NY). All participants provided written informed consent. Here we report only baseline (prior to randomization) anatomical MRI, DCE-MRI, 18F-FDG PET/CT and biomarker data from the dal-PLAQUE study.

Study population

The study population of dal-PLAQUE comprised patients with CHD or CHD risk equivalent. Patients were clinically stable and receiving appropriate treatment with a statin and/or other drugs for lowering low-density lipoprotein cholesterol (LDL-C) to achieve LDL-C levels of <100 mg/dL (<2.6 mmol/L), unless receiving maximum tolerated doses of therapy or intolerant to statins. From the 189 subjects screened in the dal-PLAQUE trial, 40 were included in this study.

Image acquisition

PET/CT All PET scanners were fully calibrated and corrections applied for attenuation, isotope decay, dead time, normalization, sensitivity, scatter and random coincidences. Patients were instructed to avoid meals rich in carbohydrates starting from 12 h before 18F-FDG injection. Additionally subjects were asked to abstain from heavy physical activity for 24 h before imaging to reduce muscle uptake of 18F-FDG. Approximately 30 min before 18F-FDG injection, glucose was measured: if fasting blood glucose was higher than 200 mg/dL, imaging was rescheduled, otherwise patients were injected with 15 mCi (555 MBq) 18F-FDG, bought commercially from local vendors. After 120 min of FDG circulation time [3–5], a low-dose, non-contrast-enhanced CT scan was performed for attenuation correction and anatomical
coregistration. After aortic imaging for the purpose of the trials, carotid PET data were acquired in 3-D mode for 15 min using one bed position with the superior aspect of the field of view being the internal auditory meatus.

Anatomical MRI Carotid MRI was performed on 1.5-T clinical whole-body systems (Siemens Medical Solutions, Erlangen, Germany) in the head-first supine position using a four-channel carotid array (Machnet, Netherlands) for signal reception. Sixteen non-overlapping cross-sectional T1-weighted (echo time, TE, 9 ms; repetition time, TR, 800 ms), T2-weighted (TE 56 ms; TR 2,000 ms) and proton density-weighted (PD-weighted; TE 9 ms, TR 2,000 ms) images were obtained using multislice, fat-saturated 2-D turbo spin echo (TSE) acquisitions starting at, and extending below, the left carotid bifurcation as previously described [14, 15]. Dark blood was obtained using in-flow and out-flow saturation. Other relevant imaging parameters common to all three acquisitions were: field of view 140×140 mm, matrix size 256×256, in-plane spatial resolution 0.55×0.55 mm, slice thickness 3 mm, interslice gap 0.3 mm, excitation flip angle 90°, refocusing angle 180°, turbo factor 15, one signal average, 100 measurements.

DCE-MRI DCE-MRI was performed on one selected axial slice (chosen from the T1-weighted image set, as the slice with the greatest degree of carotid wall thickening) using a black-blood, fat-saturated TSE sequence after injection of 0.2 mmol/kg gadolinium-diethylene triamine pentaacetic acid (Gd-DTPA, Magnevist; Bayer Schering Pharma) [6]. Black blood was obtained using a double inversion recovery technique. Relevant imaging parameters were: TE 5.6 ms, TR 250 ms, field of view 140×140 mm, matrix size 256×256, in-plane spatial resolution 0.55×0.55 mm, slice thickness 3 mm, excitation flip angle 90°, refocusing angle 180°, turbo factor 15, one signal average, 100 measurements.

More details on the PET and MRI acquisition parameters are provided by Fayad et al. [14, 15]. For the purpose of this comparison, only data from 4 of the 11 imaging sites passed our imaging quality control to ensure uniformity between MRI protocols, vendors and field strength.

Image analysis

A schematic representation of the image analysis is shown in Fig. 1.

Measurement of 18F-FDG uptake PET/CT images were analyzed using Osirix (Geneva, Switzerland; http://www.osirix-viewer.com/) and in-house software for data handling. Arterial
\(^{18}\text{F-FDG}\) uptake was measured by drawing circular regions of interest (ROI) on all PET/CT slices of both common carotid arteries. ROIs were fitted to the artery wall on each axial slice, while coronal and sagittal views were used to ensure that uptake was from the artery. Whole-vessel mean, maximum and mean of maximum standardized uptake values (SUV) were recorded. Arterial SUV was normalized to the blood pool SUV measured from five slices in the jugular vein to calculate the whole-vessel mean, maximum and mean of maximum arterial target-to-background ratio (TBR) \([5]\). SUV and TBR are both well-validated measures of \(^{18}\text{F-FDG}\) uptake. To account for possible misregistration errors between DCE-MRI and PET/CT data, we recorded mean, maximum and mean of maximum SUV and TBR across five slices centered on the slice matching the DCE slice (Fig. 1, approximately 1-cm segment).

**Anatomical MRI** Inner and outer vessel wall contours were manually traced by an experienced observer on all slices for both common carotid arteries using T2-weighted multislice 2-D TSE images. Mean lumen diameter, vessel diameter, lumen area, wall area, total vessel area, mean wall thickness, standard deviation of wall thickness and normalized wall index for each slice were calculated using a customized software program (Vessel Mass Software; Leiden University Medical Center, The Netherlands) as previously described \([17]\), and interfaced with in-house custom software for data analysis. Whole-vessel parameters were recorded, as well as single slice values matched with DCE-MRI acquisition. Plaque components were classified by an experienced observer by looking simultaneously at the T1-, T2- and PD-weighted multislice 2-D TSE acquisitions to assess the presence or absence of LRNC, calcification and intraplaque hemorrhage, as described by Fayad et al. \([14, 15]\). Plaques were characterized across the whole vessel as well as on the slice matching with the DCE-MRI acquisition.

**DCE-MRI** The uptake of contrast agent was evaluated with a custom-made MATLAB (The MathWorks Inc., Natick, MA) program \([6]\). To ensure proper calibration between different imaging sessions, curves were converted to contrast agent concentrations using the spoiled gradient echo signal model \([18]\) and the widely accepted linear relationship between relaxation rates and concentration. Contrast agent relaxivity was assumed to be 4.3 \(\text{mmol}^{-1} \text{s}^{-1}\) \([19]\). Kinetic modeling was performed using a population arterial input function (AIF) \([20]\) and the model of Tofts et al. with modification \([21]\). Kinetic parameters \(v_p\) (fraction of vascular space), \(K^{\text{trans}}\) (wash-in constant from plasma to tissue compartment), \(v_e\) (fraction of extravascular extracellular space), and \(K_{ep}\) (wash-out constant from tissue to plasma compartment) were calculated using standard nonlinear least squares fittings \([22]\) in MATLAB. The non-model based parameter area under the concentration curve (AUC) \([6, 10–12]\) was also calculated at 1 min (AUC1) and 2 min (AUC2) after injection of contrast agent \([6]\) (Fig. 1).

**Image coregistration between \(^{18}\text{F-FDG PET/CT and DCE-MRI\)** Anatomical coregistration between the DCE-MRI slice and the corresponding PET/CT slice was performed using automated registration of the CT- and PD-weighted high-resolution MR images using a Leonardo workstation (Siemens Medical Solutions, Erlangen, Germany). When necessary, manual adjustments were applied to correct for misalignments in the automated registration.

**Statistical methods**

The main goal of our analysis was to correlate perfusion metrics by DCE-MRI with plaque inflammation as measured by \(^{18}\text{F-FDG PET/CT\). We also assessed the correlation between: (a) whole-vessel PET/CT and whole-vessel anatomical MRI variables and (b) single-slice perfusion measures by DCE-MRI with matching single-slice anatomical MRI variables. Correlations were calculated using a mixed linear model with a compound symmetric correlation structure \([23]\), implemented with PROC MIXED in SAS v. 9.2. All data were natural log-transformed to achieve normality. This model accounted for the correlation between measurements of the same variable within each of the 40 patients in the study. The 95% confidence interval for each correlation coefficient was constructed using the bootstrap method \([24]\), in which 1,000 bootstrap samples of size \(n=40\) were generated. Each sample consisted of 40 subjects being sampled with replacement from the complete list of 40 subjects; for each bootstrap sample, PROC MIXED calculated a correlation coefficient from the mixed model. The distribution of these 1,000 correlation coefficients provided estimates of the 2.5th and the 97.5th percentiles as the upper and lower confidence limits for the initial point estimate. When the 95% confidence interval did not include zero (both limits had the same sign, positive or negative) the correlation was considered significantly different from zero at the 5% level of significance. To adjust for the multiple statistical tests performed, Bonferroni correction was also applied to the comparisons presented in each table in the Results section. The \(p\) value of 0.05 used to establish significance was divided by the number of comparisons considered in each table (36 for Tables 2 and 5; 24 for Table 4). Therefore, \(p<0.001\) was required for the comparisons in Tables 2 and 5, and \(p<0.02\) was required for the comparisons in Table 4 to reach statistical significance. The results are presented with and without Bonferroni correction. If correlation coefficients were less than 0.3, the correlation was considered weak; if higher or equal to 0.3 but lower than 0.7, the correlation was considered moderate; if higher or equal to 0.7, the correlation was considered strong.
Results

Patient population

The mean age of the population was 64.2 years, and most were men (78.8%). Baseline lipid biomarkers revealed average total cholesterol of 146.8 mg/dL, with average LDL-C being 74.8 mg/dL and high-density lipoprotein cholesterol (HDL-C) being 45.8 mg/dL. Baseline demographics are presented in Table 1.

Relationship between $^{18}$F-FDG PET/CT and DCE-MRI data

The relationship between DCE-MRI and PET variables was analyzed using a mixed linear model (Table 2). Comparing arterial FDG uptake by PET/CT and DCE-MRI measurements without Bonferroni correction, the non-model-based parameter AUC1 showed a weak significant inverse correlation with mean SUV, with a correlation coefficient $-0.23$. The parameter AUC2 exhibited a weak significant inverse correlation with maximum SUV (correlation coefficient $-0.21$). The model-based parameter $K^{\text{trans}}$, believed to represent a mixture of flow and permeability, exhibited weak significant inverse correlations with maximum SUV (correlation coefficient $-0.22$), mean TBR (correlation coefficient $-0.24$; Fig. 2a) and mean of maximum TBR (correlation coefficient $-0.22$). The model-based parameter $v_d$, expressing the fractional plasma volume, showed moderate inverse significant correlations with mean SUV (correlation coefficient $-0.41$) and mean of maximum SUV (correlation coefficient $-0.32$). The model-based parameter $K_{\text{ep}}$ (backflow constant from tissue to plasma) showed weak inverse significant correlations with mean SUV and TBR (correlation coefficients $-0.28$ and $-0.23$; Fig. 2b) and mean of maximum SUV and TBR (correlation coefficients $-0.24$ and $-0.20$). The model-based parameter $v_d$ did not show any significant correlations with SUV or TBR values. No significant correlations were found when using Bonferroni correction. Figure 3 shows PET/CT images and DCE-MRI uptake curves from two patients representative of our sample. The PET/CT images and Gd-DTPA uptake data are from a patient with low $^{18}$F-FDG uptake by PET/CT but high Gd-DTPA uptake by DCE-MRI (Fig. 3a–c), and a patient with high $^{18}$F-FDG and low Gd-DTPA uptake (Fig. 3d–f).

Correlation between anatomical MRI and PET/CT data

Table 3 shows the results of analysis of whole-vessel anatomical MRI data. The dataset was composed mainly of non-complex carotid atherosclerotic plaques, with calcification identified in only 15.1% and LRNC in 36.4% of the lesions. Intraplaque hemorrhage was absent from the entire cohort of subjects in this substudy. Among the slices chosen for DCE-MRI, 6.1% showed calcification and 18.2% revealed LRNC. Mean wall thickness averaged across the whole vessel calculated from anatomical MRI data showed a moderate but significant positive correlation with the average whole-vessel TBR, with a correlation coefficient 0.39 (Table 4) without Bonferroni correction. No significant correlations were found between any of the PET variables and plaque composition by MRI (data not shown). No significant correlations were found when using Bonferroni correction.

Correlation between anatomical MRI and DCE-MRI data

Analysis of high-resolution anatomical MRI data revealed that average and standard deviation of wall thickness weakly positively correlated with the DCE-MRI parameter $K_{\text{ep}}$ (correlation coefficients 0.21 and 0.25, respectively) when not using Bonferroni correction. No significant correlations were found between DCE-MRI metrics and plaque composition by MRI (data not shown). No significant correlations were found when using Bonferroni correction.

Discussion

The main goal of this study was to investigate the relationship between $^{18}$F-FDG PET/CT and DCE-MRI data from the carotid arteries of 40 patients with CHD or CHD risk equivalent recruited as part of the dal-PLAQUE study [14, 15]. These techniques offer a quantitative read-out for plaque macrophages [4] and neovessels, respectively [6, 7], two of the hallmarks of plaque vulnerability. We found a significant weak inverse relationship between the results from the two
techniques. As secondary endpoints, we explored the relationships between non-contrast-enhanced anatomical MRI data and data from both DCE-MRI and FDG PET/CT. The anatomical MRI data showed a significant weak positive correlation with the DCE-MRI data and a significant weak inverse correlation with the PET/CT data.

Previous studies have investigated the relationship between anatomical MRI and 18F-FDG PET/CT data and found higher FDG uptake in complex lesions, but no or only a weak correlation with plaque wall thickness. Silvera et al. found higher FDG uptake in lipid-based compared to collagen-rich or calcified plaques using TBR [25]. Additionally (only in the LRNC group), they found a significant variation in TBR according to the median of the vessel wall thickness. On the contrary, Kwee et al. [26] found higher FDG uptake measured as SUV in fibrous, but not lipid-rich, plaques. Additionally, they found a correlation between SUV and vessel wall volume. In this study, we confirmed a significant relationship between average whole vessel TBR by PET/CT and average wall thickness by anatomical MRI, but fail to demonstrate a correlation between FDG uptake and plaque composition (Table 4). This difference from the two studies mentioned above may be due to the patient population and nature of the lesions (more complex in other studies, versus non-complex in the present study). Additionally, we demonstrate weak but significant correlations between anatomical MRI measures such as average wall area and average and standard deviation of wall thickness and the DCE-MRI metric $K_{ep}$, while no correlation was found with plaque composition (Table 5).

Recently, Cyran et al. [27] studied the relationship between 18F-FDG PET/CT and DCE-MRI results in patients with supraaortic arteritis, and found a positive significant correlation between mean arterial TBR and extraction fraction of MRI contrast agent. Taqueti et al. [28] also found a positive significant correlation between FDG uptake measured as TBR and $K_{trans}$ by DCE-MRI and neovessels by histology in patients with severe carotid stenosis. In this study we found a weak but significant inverse correlation between model-based and non-model-based DCE-MRI metrics and SUV and TBR by PET/CT. There may be several reasons for this difference in findings. Firstly, it must be noted that the patient populations in the two studies were very different: while Taqueti et al.
[28] studied subjects presenting with a high degree of carotid stenosis, in this study we investigated subjects with non-complex atherosclerotic lesions (Table 3). Differences in medication usage between the population investigated in this study and other studies may also act as a confounding factor. Additionally, while it is known that PET/CT and DCE-MRI provide an indication of the extent of plaque macrophages and neovessels, their metrics may not exclusively reflect these histological features. For example, contrast agent extravasation in DCE-MRI depends not only on neovessel density and permeability, but also on the fractional extravascular extracellular space available for contrast agent distribution [21]. Alternatively, it is possible that plaque macrophage content and neovascularization (and therefore 18F-FDG uptake on PET and Gd-DTPA uptake on DCE-MRI) may exhibit different relationships with each other depending on the stage of the plaque that is being imaged.

Another potential explanation for our findings resides in the interplay between neovascularization, hypoxia and inflammation [29]. It is relatively well established that hypoxia and inflammation...

Table 2 Correlation between DCE-MRI and slice-matched 18F-FDG PET/CT parameters (n=40)

<table>
<thead>
<tr>
<th>PET/CT parameters</th>
<th>DCE-MRI parameters</th>
<th>AUC1</th>
<th>AUC2</th>
<th>Ktrans</th>
<th>vc</th>
<th>Kep</th>
<th>vp</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUV_Mean</td>
<td></td>
<td>-0.23</td>
<td>-0.22</td>
<td>-0.25</td>
<td>0.02</td>
<td>-0.28</td>
<td>-0.41</td>
</tr>
<tr>
<td>SUV_Max</td>
<td></td>
<td>-0.18</td>
<td>-0.21</td>
<td>-0.22</td>
<td>-0.04</td>
<td>-0.20</td>
<td>-0.25</td>
</tr>
<tr>
<td>SUV_MeanofMax</td>
<td></td>
<td>-0.20</td>
<td>-0.20</td>
<td>-0.22</td>
<td>0.02</td>
<td>-0.24</td>
<td>-0.32</td>
</tr>
<tr>
<td>TBR_Mean</td>
<td></td>
<td>-0.23</td>
<td>-0.20</td>
<td>-0.24</td>
<td>-0.02</td>
<td>-0.23</td>
<td>-0.30</td>
</tr>
<tr>
<td>TBR_Max</td>
<td></td>
<td>-0.10</td>
<td>-0.11</td>
<td>-0.15</td>
<td>-0.14</td>
<td>-0.04</td>
<td>-0.29</td>
</tr>
<tr>
<td>TBR_MeanofMax</td>
<td></td>
<td>-0.20</td>
<td>-0.19</td>
<td>-0.22</td>
<td>-0.04</td>
<td>-0.20</td>
<td>-0.29</td>
</tr>
</tbody>
</table>

Bold type indicates a significant correlation without Bonferroni correction (P<0.05)

DCE-MRI a, d FDG PET image overlain on CT image (blue circles common carotid artery, red circles jugular vein). b, e T1-W MRI image after contrast agent administration. c, f Kinetic modeling of Gd-DTPA uptake by DCE-MRI (blue dots experimental data, red line model fit). SM skeletal muscle, L vessel lumen

Table 3 Non-contrast-enhanced MRI analysis

<table>
<thead>
<tr>
<th>Measure (mean and standard deviation)</th>
<th>Whole vessel (n=33)</th>
<th>DCE-MRI slice (n=40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average total vessel area (cm²), mean (SD)</td>
<td>0.61 (0.20)</td>
<td>0.60 (0.13)</td>
</tr>
<tr>
<td>Average wall area (cm²), mean (SD)</td>
<td>0.28 (0.11)</td>
<td>0.24 (0.06)</td>
</tr>
<tr>
<td>Average lumen area (cm²), mean (SD)</td>
<td>0.32 (0.11)</td>
<td>0.36 (0.08)</td>
</tr>
<tr>
<td>Average mean wall thickness (mm), mean (SD)</td>
<td>1.15 (0.24)</td>
<td>0.97 (0.20)</td>
</tr>
<tr>
<td>Average standard deviation of wall thickness (mm), mean (SD)</td>
<td>0.27 (0.19)</td>
<td>0.20 (0.11)</td>
</tr>
<tr>
<td>Average normalized wall index*, mean (SD)</td>
<td>0.46 (0.07)</td>
<td>0.40 (0.06)</td>
</tr>
<tr>
<td>Calcification, n (%)</td>
<td>5 (15.1)</td>
<td>2 (6.1)</td>
</tr>
<tr>
<td>Hemorrhage, n (%)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Lipid rich necrotic core, n (%)</td>
<td>12 (36.4)</td>
<td>6 (18.2)</td>
</tr>
</tbody>
</table>

* Wall area/total vessel area based on the average of the right and left carotid arteries
inflammation are intertwined at the molecular, cellular and clinical levels [30]. Hypoxic conditions are known to develop in atherosclerotic plaques as a result of smooth muscle cell proliferation in the tunica intima, subsequent wall thickening, and increased oxygen consumption by macrophages and foam cells [31–33]. Hypoxia induces increased glycolysis [34, 35] in macrophages (hence increased FDG uptake). In addition to increasing macrophage glycolysis, hypoxia is known to increase macrophage activation, phagocytosis [36] and tumor necrosis factor production [37]. This hypothesis offers a possible explanation for our findings, where higher FDG uptake was inversely correlated with plaque neovascularization shown by DCE-MRI. It is therefore possible to envision a scenario where the hypoxia-driven inflammatory response may precede an increase in plaque neovascularization by neoangiogenesis [38]. This hypothesis has been corroborated by more recent in vivo findings by Pedersen et al. [39], which show the relationship between SUV and expression of genes of plaque vulnerability and neoangiogenesis in human carotid specimens. Pedersen et al. found a significant but negative correlation between CD34, a histological marker of microvessel density, and both SUV by $^{18}$F-FDG-PET and CD68, a histological marker of macrophages. No correlation was found between SUV and markers of neoangiogenesis (vascular endothelial growth factor). The authors concluded that $^{18}$F-FDG uptake inversely reflects microvessel density, but not neoangiogenesis in human atherosclerotic plaques. Since DCE-MRI metrics are known to reflect plaque neovessel content, this may explain the higher substantial $^{18}$F-FDG uptake in areas of low uptake of Gd-DTPA on DCE-MRI and vice versa.

Together with other studies, our findings suggest that $^{18}$F-FDG PET and DCE-MRI may offer complementary, non-overlapping information about vascular inflammation and neoangiogenesis. This suggests that these two techniques may be used in combination in future clinical practice for accurate staging and risk stratification of atherosclerotic plaques. However, a more thorough investigation of these two modalities and their underlying histological correlates at the different stages of plaque progression is needed before their clinical use.

### Study limitations

Possible limitations of the study are as follows. Firstly, the sample size was relatively small (40 subjects) and comparison of the imaging findings with a histological gold standard was not possible. Due to the small sample size, subgroup analyses of symptomatic versus asymptomatic subjects were also not possible. Secondly, DCE-MRI achieved limited single-slice coverage to maintain sufficiently fast temporal resolution (4.8 s) together with a high spatial resolution (0.5×0.5 mm) for the reliable estimation of contrast agent uptake and good characterization of plaque composition. This required careful matching of DCE-MRI slices with the corresponding anatomical MRI and PET/CT images, which may be affected by misregistration. The development of novel technologies such as integrated PET/MRI scanners will, in the future, allow these studies to be performed simultaneously, naturally providing coregistered PET and MRI images, and therefore eliminating this issue [40]. PET imaging has quite poor spatial resolution for imaging small structures, such as atherosclerotic vessel walls. However, this modality has been used successfully in combination with CT, which provides anatomical details and attenuation correction, to quantify inflammation in atherosclerotic plaques [4]. PET/MRI may allow the application of partial volume correction techniques to help image small structures, such as the vasculature, with increased accuracy [41].

A black-blood sequence was chosen for DCE-MRI acquisition to allow better delineation of these non-complex atherosclerotic lesions from the vessel lumen during dynamic scanning. Despite allowing clear visualization of the arterial vessel wall by suppressing the blood signal, black-blood imaging does not allow sampling a per-patient AIF for kinetic

| Table 4 Correlation between anatomical MRI and whole-vessel PET/CT data |
|---------------------------------|----------------|---------|-----------|---------|
|                                  | Average SUV  | Maximum SUV | Average TBR | Maximum TBR |
| Average total vessel area (cm$^2$) | 0.04 | 0.00 | 0.12 | 0.08 |
| Average wall area (cm$^2$)       | 0.05 | 0.00 | 0.29 | 0.23 |
| Average lumen area (cm$^2$)      | 0.03 | 0.01 | −0.09 | −0.10 |
| Average mean wall thickness (mm) | 0.05 | 0.01 | **0.39** | 0.33 |
| Average standard deviation of wall thickness (mm) | 0.01 | −0.03 | 0.30 | 0.24 |
| Average normalized wall index    | 0.04 | 0.01 | 0.33 | 0.29 |

Bold type indicates a significant correlation without Bonferroni correction ($P<0.05$)
modeling. A population-derived AIF [20] was used for analysis, which may have introduced inaccuracies into the calculation of model-based parameters. Finally, no significant correlations were found when using Bonferroni correction. While Bonferroni correction is applied when multiple statistical tests are performed to avoid type 1 errors (false positives), it is a rather conservative approach which does increase the chance of type 2 errors (false negatives). While some of the correlations reported without Bonferroni correction are likely to have been false positives, in this case the correction demands \( p < 0.001 \) (Tables 2 and 5) and \( p < 0.002 \) (Table 4) to reach significance. As this may conceivably have led to some false negatives, both corrected and uncorrected results are reported.

**Conclusion**

In conclusion, in this study we found a significant inverse relationship between non-model and model-based perfusion indices by DCE-MRI (indices of neovascularization) and SUV and TBR by PET/CT (markers of macrophage content). This finding, in combination with other findings in the literature, suggests that there may be a complex relationship between plaque inflammation and neovascularization, and that \(^{18}\)F-FDG PET and DCE-MRI images have complex histological correlates, whose relationship may change during plaque progression. The combination of PET/CT and DCE-MRI imaging may prove to be a useful tool in drug development for proof of concept of new therapies.

**Acknowledgments** F. Hoffmann-La Roche Ltd funded the dal-PLAQUE study and provided third-party editorial support, through Prime Healthcare Ltd, for the preparation of the manuscript. C.C. acknowledges grant and research support from the National Institutes of Health and National Heart Lung and Blood Institute (NIH/NHLBI R01 HL071021, NIH/NHLBI R01 HL078667 and NIH/NICRR UL1RR029887).

**Conflicts of interest** S.R., D.J.-G., A.M., D.R., J.B., E.M., J.G. and V.F. indicate that they have nothing to disclose. VM discloses that he has received research grants from Roche, BMS and Novartis, and acted as a consultant to Genentech. J.H.F.R. discloses that he has received honoraria from Roche. D.K. is an employee of F. Hoffmann-La Roche. M.W. discloses that he received honoraria from Roche, BMS and Novartis, and research grants from Merck, BMS, Genentech, GSK and VBL. M.W. discloses that he has received honoraria from Roche. D.K. is an employee of F. Hoffmann-La Roche. M.E.F. discloses that he has received honoraria from Roche and is part-supported by the National Institute for Health Research Cambridge Biomedical Research Centre. Z.A.F. discloses that he has received research grants from Roche, GlaxoSmithKline, Merck, VBL Therapeutics, Novartis, Bristol-Myers Squibb, and Via Pharmaceuticals, and honoraria from Roche.

**References**


